Somatic Mutation Testing

Testing for the presence of cancer requires the utmost personal care and consideration. Somatic mutation testing is enormously beneficial for improving the prognosis and the quality of life of cancer-affected patients. Our team of hereditary and somatic cancer experts will support you during every step of the process.

Our portfolio for somatic mutation testing

Identifying Somatic Mutations for Tumor Profiling

Every cancer cell can evolve its own pattern of mutated genes.

Each person's cancer, and even parts of a single tumor, can become completely unique. This has implications with respect to diagnosis, prognosis and treatment response. The presence of recurrent somatic mutations allows us to create a detailed molecular fingerprint of the tumor and to identify important tumor subtypes.

How Can Somatic Genetic Testing Help Patient Care?

Somatic mutation analysis is a standard of practice for tumors in order to identify therapeutic sensitizing and resistance mutations. This allows a finer assessment of the diagnosis and prognosis and targeted therapies directed towards the individual patients tumor profile.

What Do We Know About Somatic Mutations?

Cancer is one of the leading causes of morbidity and mortality worldwide. Cancer can be the result of a genetic predisposition that is inherited from family members (germline (hereditary) gene mutation) or it can be the result of the acquired mutations accumulated during a lifetime (somatic (acquired) mutation).

Unlike regular cells, cancer cells do not experience physiological elimination of “programmed cell death” or “apoptosis”; instead they continue to grow and divide. Tumor cells show uncontrolled proliferation if there are mutations in the genes involved in cell division .

Somatic Mutation Testing for Myeloid Tumors

Genetic testing of myeloid tumors can help you make accurate diagnoses, provide prognoses, choose appropriate therapy and counsel patients

Learn more

Note

Hotspot targeted mutation testing is unavailable in the US for the following mutations: BRAF c.1799T>A p.V600E, EGFR c.2573T>G, p.L858R, KRAS c.35G>A, p.G12D, KRAS c.38G>A, p.G13D, KRAS c.35G>T p.G12V, NRAS c.181C>A p.Q61K, NRAS c.34G>T, p.G12C, NRAS c.35G>A, p.G12D, NRAS c.182A>G, p.Q61R.

Resources

Downloads

CENTOGENE Productsheet Solid Tumor Panel English

Solid Tumor Panel – Product Sheet

Providing knowledge to battle cancer

CENTOGENE Myeloid Productsheet English PDF

Myeloid Tumor Panel – Product Sheet

The targeted approach to detecting myeloid malignancies

Scientific Publications

Linking Seizures and Amino Acid Homeostasis

Seizures are part of the phenotypic spectrum in numerous rare disorders, but the underlying pathophysiology is rarely understood. For a novel seizure syndrome, the transmembrane transport of certain […]

Loading...

Related Webinars

Variant Reclassification: When, Why, How

Discover how CENTOGENE’s variant reclassification enables us to provide you with the latest and highest quality data for the most up-to-date diagnosis.

Loading...

What You Need to Know about Carrier Screening

Carrier screening is a predictive genetic testing, designed for future parents. Would you like to learn more and understand it better? Watch our recorded webinar about CentoScreen®: "What you need to […]

Loading...

Clinical Exome Sequencing Targets Genes Associated with All Known Clinical Phenotypes

Watch our recorded webinar, “Clinical Exome Sequencing targets genes associated with all known clinical phenotypes to achieve high diagnostic accuracy” and find out how clinical utility meets patient […]

Webinar
26 Jan, 2018
Loading...

Get in Touch With Our Customer Support

Our consultation service is available in several languages.

+49 (0) 381 80 113 - 416

Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET

Contact Us

For our US Partners:

+1 (617) 580 - 2102

Mon. – Fri. 9 a.m. – 5:30 p.m. EST


Contact Us